stoxline Quote Chart Rank Option Currency Glossary
  
Aadi Bioscience, Inc. (AADI)
2.05  -0.05 (-2.38%)    03-18 16:00
Open: 2.15
High: 2.19
Volume: 62,607
  
Pre. Close: 2.1
Low: 2.015
Market Cap: 95(M)
Technical analysis
Short term     
Mid term     
Targets 6-month :  1-year : 
Resists First :  Second : 
Pivot price
Supports First :  Second : 
MAs MA(5) :  MA(20) : 
MA(100) :  MA(250) : 
MACD MACD :  Signal : 
%K %D K(14,3) :  D(3) : 
RSI RSI(14):
52-week High :  Low : 
Price, MAs and Bollinger Bands


Stock Price Prediction
If tomorrow: Open lower Open higher
High: - -
Low: - -
Close: - -
Company Description

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

Headline News

Tue, 10 Mar 2026
Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027 - MarketBeat

Tue, 03 Mar 2026
Aadi Bioscience Conference: Whitehawk CEO Details 3-Program ADC Pipeline, First Data Seen in 2027 - Yahoo Finance

Sat, 21 Feb 2026
Aadi Bioscience to Participate in the Jefferies Healthcare Confe - GuruFocus

Thu, 24 Apr 2025
Aadi Bioscience Stock Price, News & Analysis - Stock Titan

Wed, 02 Apr 2025
Whitehawk Therapeutics - The Pharma Letter

Wed, 26 Mar 2025
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - PR Newswire

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders (%)
Held by Institutions (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS
EPS Est Next Qtrly
EPS Est This Year
EPS Est Next Year
Book Value (p.s.)
Profit Margin %
Operating Margin %
Return on Assets (ttm) %
Return on Equity (ttm) %
Qtrly Rev. Growth %
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio
PEG Ratio
Price to Book value
Price to Sales
Price to Cash Flow
Stock Dividends
Dividend
Forward Dividend
Dividend Yield 0%
Dividend Pay Date
Ex-Dividend Date

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android